Online Program Home
My Program

CC = Vancouver Convention Centre   F = Fairmont Waterfront Vancouver
* = applied session       ! = JSM meeting theme

Activity Details

336 * ! Tue, 7/31/2018, 10:30 AM - 12:20 PM CC-West 224
Surrogate Endpoints: Bridging the Roles of Biology and Statistics for Clinical Outcome Prediction — Topic Contributed Papers
Biopharmaceutical Section
Organizer(s): Hong Tian, Janssen Pharmaceutical
Chair(s): Sue-Jane Wang, Center for Drug Evaluation and Research U.S. Food and Drug Administration
10:35 AM On the Relationship Between the Causal-Inference and Meta-Analytic Paradigms for the Evaluation of Surrogate Endpoints
Geert Molenberghs, Universiteit Hasselt & Katholieke Universiteit Leuven
10:55 AM Assessment of Biomarkers and Surrogate Endpoints in Drug Development

Ivan Chan, AbbVie Inc; Shu-Chih Su, Merck Research Labs
11:15 AM Limitations of Progression Free Survival as a Surrogate Marker for Overall Survival in Oncology Trials

Robin Mogg, Merck Research Laboratories; Yiwei Zhang, Merck Research Laboratories
11:35 AM Identifying and Validating Surrogate Endpoints for Overall Survial (OS) in Metastatic Castration-Resistant Prostate Cancer

Xiaowei Guan, Pfizer, Inc.; Michelle Casey, Pfizer, Inc.; De Phung, Astellas Pharma, Inc. ; Suha Sari, Pfizer, Inc.; Eren Demirhan, Pfizer, Inc.
11:55 AM Discussant: Vladimir Dragalin, Janssen R&D
12:15 PM Floor Discussion